Basic Information
| LncRNA/CircRNA Name | ABHD11-AS1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | ENSG00000225969 |
| Refseq | NR_026690 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic cancer |
| ICD-0-3 | C25 |
| Methods | qPCR, Western blot, in vitro knockdown, etc. |
| Sample | pancreatic tumor tissue, Human PC cell lines (Capan-2, L3.6pl, BxPC3, AsPC-1 and PANC-1) and pancreatic cell line HPDE6-C7 |
| Expression Pattern | up-regulated |
| Function Description | the expression of ABHD11-AS1 was significantly increased in both PC tissues and cell lines. The clinical analysis revealed that a high level of ABHD11-AS1 expression was correlated with distant metastasis, TNM stage, and tumor differentiation. The Kaplan- Meier analysis showed that high ABHD11- AS1 expression levels predicted poorer survival. Moreover, univariate and multivariate analyses confirmed that the expression of ABHD11- AS1 was an independent and significant factor associated with poor overall survival rates. Loss-of-function experiments showed that the knockdown of ABHD11-AS1 suppressed PC cell proliferation, migration, invasion, and EMT in vitro. Mechanistically, the knockdown of ABHD11- AS1 decreased phospho(p) AKT and phospho(p) PI3K expression, but did not affect the AKT and PI3K expression in PC cells |
| Pubmed ID | 30575903 |
| Year | 2018 |
| Title | Long noncoding RNA ABHD11-AS1 predicts the prognosis of pancreatic cancer patients and serves as a promoter by activating the PI3K-AKT pathway |
External Links
| Links for ABHD11-AS1 | GenBank HGNC NONCODE |
| Links for pancreatic cancer | OMIM COSMIC |